从毒素到治疗:关于使用肉毒素治疗自主功能障碍的叙述性审查
Lucas Rempel1, Raza N Malik1,2, Claire Shackleton1,2
1International Collaboration on Repair Discoveries, Faculty of Medicine, The University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Toxins
|February 23, 2024
概括
毒素是一种强大的神经毒素,越来越多地用于治疗. 本综述详细介绍了它在治疗自主功能障碍方面的有效性和安全性,涵盖了各种配方和剂量.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 毒素是一种来自Clostridium botulinum的神经毒素,抑制了乙胆的传播,导致肌肉疲软.
- 它的抗胆性质表明了对胆性相关疾病的治疗潜力.
- 自主神经系统 (ANS) 功能障碍包括影响各种器官系统的各种疾病.
研究的目的:
- 提供关于肉毒素在治疗自主功能障碍中的治疗用途的全面审查.
- 总结可用的配方,剂量和临床结果.
- 为了突出与毒素治疗ANS疾病相关的不良事件.
主要方法:
- 这项研究是对现有文献的叙述性审查.
- 它综合了关于肉毒素在治疗自主功能障碍中的有效性和安全性的数据.
- 该审查审查了各种肉毒毒素配方及其剂量.
主要成果:
- 毒素已经在各种自主功能障碍中证明了治疗效益.
- 不同的配方和剂量表现出不同的疗效和安全性.
- 在治疗的背景下报告和分析不良事件.
结论:
- 毒素是针对特定自主功能障碍的可行的治疗选择.
- 需要进一步的研究来优化配方和剂量,以获得最大的益处.
- 理解不良事件对于安全的临床应用至关重要.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
681
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
681
Skeletal Muscle Relaxants: Therapeutic Uses
486
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
486
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
674
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
674
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
421
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
421
Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K


